
Three medical oncologists at Florida Cancer Specialists & Research Institute co-author a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

Three medical oncologists at Florida Cancer Specialists & Research Institute co-author a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

Delta variant lowers COVID-19 vaccine effectiveness to 66%; Johnson & Johnson reports booster shot results; cancer center reports mask, vaccine preferences of patients.



Day 1 of this year’s virtual Community Oncology Conference opened with a panel discussion that touched on all things related to the COVID-19 pandemic, with leaders presenting a unified front.

Luis Carrascosa, MD, a radiation oncologist at the Florida Cancer Specialists Ocala Cancer Center, discusses new and upcoming trends in radiation therapy for prostate cancer.

Florida Cancer Specialists has integrated SpaceOAR Hydrogel into its armamentarium as a pre-treatment for radiation therapy in prostate cancer patients.

The COVID-19 pandemic has impacted specialty practices generally and oncology practices especially have been resilient throughout the pandemic.

Nathan H. Walcker will succeed Brad Prechtl on August 1, 2020.

Experts from Florida Cancer Specialists will cover how the COVID-19 pandemic is transforming telemedicine in oncology by addressing billing, operations, training and provider perspectives on Monday, April 20, 2020.

“Quest for Value: Advancing Oncology Value-based Care,” this year’s first installment in the Institute for Value-Based Medicine (IVBM) from The American Journal of Managed Care®, zeroed in seniors, a population that’s growing not just in Florida but across the United States. Older Americans are more likely to develop cancer, but thanks to better detection and treatment, they are more likely to survive cancer, too.

Florida Cancer Specialists & Research Institute and Humana Inc. have signed a new multiyear agreement that provides Humana members with in-network access to FCS’ comprehensive range of oncology services.

A 28% reduction in hospital admissions leads to a broader agreement, the physicians' group and payer say.